Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s ...

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...

Pfizer will pay China’s 3SBio $1.25 billion upfront to gain access to a cancer therapy that could rival Akeso and Summit’s ...

3SBio will grant Pfizer exclusive global rights, not including China, to develop, manufacture and commercialize SSGJ-707, a ...

Pfizer just penned a $6 billion licensing deal with China's 3SBio to develop and commercialize a cancer drug, SSGJ-707. The ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

A top court on Wednesday ruled that the European Commission had failed the transparency test by declining to release text ...

digital-first platform powered by Roadzen’s Global Dealer Network (GDN) platform. With dealership clients already onboarding, Roadzen believes that the partnership is poised to generate seven ...

KUALA LUMPUR, Malaysia, May 06, 2025 (GLOBE NEWSWIRE) -- Sagtec Global Limited (NASDAQ: SAGT) (“Sagtec” or the “Company”), a leading provider of ...

The organization said it is actively seeking new global partners. "Since its inception, the GAPP Partnership Program has proven to be very effective in building awareness and demand for Wild ...